Back

Human hepatocyte PNPLA3 148M exacerbates rapid non-alcoholic steatohepatitis development in chimeric mice

Kabbani, M.; Michailidis, E.; Steensels, S.; Fulmer, C. G.; Luna, J. M.; Le Pen, J.; Tardelli, M.; Razooky, B.; Ricardo-Lax, I.; Zou, C.; Zeck, B.; Stenzel, A. F.; Quirk, C.; Foquet, L.; Ashbrook, A. W.; Schneider, W. M.; Belkaya, S.; Lalazar, G.; Liang, Y.; Pittman, M.; Devisscher, L.; Suemizu, H.; Theise, N. D.; Chiriboga, L.; Cohen, D. E.; Copenhaver, R.; Grompe, M.; Meuleman, P.; Ersoy, B. A.; Rice, C. M.; de Jong, Y. P.

2020-11-20 pathology
10.1101/2020.11.19.387613 bioRxiv
Show abstract

Advanced non-alcoholic fatty liver disease (NAFLD) is a rapidly emerging global health problem associated with pre-disposing genetic polymorphisms, most strikingly an isoleucine to methionine substitution in patatin-like phospholipase domain-containing protein 3 (PNPLA3-I148M). Here, we study how human hepatocytes with PNPLA3 148I and 148M variants engrafted in the livers of chimeric mice respond to a hypercaloric Western-style diet. As early as 4 weeks, mice developed dyslipidemia, impaired glucose tolerance, and steatohepatitis selectively in the human graft, followed by pericellular fibrosis after 8 weeks of hypercaloric feeding. The PNPLA3 148M variant, either from a homozygous 148M human donor or overexpressed in a homozygous 148I donor background, caused widespread microvesicular steatosis and even more severe steatohepatitis. We conclude that PNPLA3 148M in human hepatocytes exacerbates NAFLD. These models will facilitate mechanistic studies into human genetic variants associated with advanced fatty liver diseases.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.